Navigation Links
XTL Provides Update on Phase I Clinical Trial of XTL-2125

VALLEY COTTAGE, New York, June 06, 2007 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced today that it has completed the analysis of results from a Phase I clinical trial with XTL-2125 in patients with chronic Hepatitis C. This Phase I trial was a placebo controlled, randomized, dose escalating study, which evaluated the safety, tolerability and antiviral activity of single and multiple doses of XTL-2125. The study enrolled 56 patients into seven cohorts comprised of eight patients each (of which two are placebo patients). Each patient received a single dose, followed by a 14-day multi-dosing regimen commencing one week after the single dose administration. The highest daily multi-dose regimen that was evaluated in the trial was 1800mg per day (600mg three times per day).

The analysis of the data indicates that XTL-2125 was generally well tolerated. However, HCV-RNA viral load reductions in patients treated with XTL-2125 were not significantly different from those observed in the placebo group. Based on these results, XTL has decided to suspend further development of XTL-2125.

XTL's CEO, Ron Bentsur, commented: "The completion of this Phase I trial concludes our research on the XTL legacy compounds that we inherited. Through an aggressive business development effort, XTL's new management team has successfully reinvented the company's product portfolio - with Bicifadine as a lead product in late stage clinical development, and the XTL-DOS program, which is emerging as a very promising program in Hepatitis C. We look forward to an exciting rest of 2007, with the initiation of a late-stage clinical trial with Bicifadine in chronic neuropathic pain, and the initiation of IND-enabling studies with a novel hepatitis C inhibitor from the XTL-DOS program. We will also continue to opportunistically seek to broaden our portfolio through the in-licensing and acquisitions of additional clinical
'"/>




Page: 1 2 3

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
3. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
4. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
5. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
8. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
9. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
10. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
11. NeoPharm Provides Update on LE-SN38 Program
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: XTL Provides Update Phase Clinical Trial XTL
(Date:6/29/2015)... , June 29, 2015  Daktari Diagnostics was honored at ... Technology in the Service of Society Award. IEEE President and ... Barry L. Shoop presented the award to Principal Scientist ... ceremony was held Saturday, June 20, 2015, at the historic ... . "I have spent more than 3 ...
(Date:6/29/2015)... June 29, 2015  New guidelines released today ... Association give hope for better outcomes to the ... acute ischemic stroke each year. Stryker,s Trevo ® ... used in the clinical trials that provided data ... guidelines strongly recommend endovascular therapy with stent retrievers ...
(Date:6/29/2015)... Nev. , June 29, 2015  PDL BioPharma, ... has entered into a credit agreement with CareView Communications, ... up to $40 million of secured debt financing. CareView ... focused on patient care monitoring. Under the ... $40 million of debt financing in two tranches of ...
Breaking Medicine Technology:Daktari Honored with IEEE Spectrum Award 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 2New AHA Guidelines For The Early Management And Treatment Of Stroke Will Change The Standard Of Care For Thousands Of Stroke Patients Each Year 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4
... Oct. 24, 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ... & Drug Administration (FDA) has scheduled a meeting of ... 2011, at which the ADASUVE New Drug Application (NDA) ... that the FDA had accepted the resubmission of the ...
... 2011 Covance Inc. (NYSE: CVD ) ... Shanghai, China, has received Good Laboratory Practice (GLP) certification ... the Organization for Economic Cooperation and Development (OECD). The ... toxicology, in-vivo PK screening, and metabolism services. ...
Cached Medicine Technology:Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011 2Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011 3Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China 2
(Date:6/29/2015)... NEW YORK (PRWEB) , ... June 29, 2015 ... ... apnea (OSA) is now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. The device ... Administration and is an alternative to continuous positive airway pressure (CPAP), the current ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors ... Webinar**, July 16, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors ... human factors engineering to the design of new products as well as to ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... developed a new approach to build nearly complete genomes by combining high-throughput DNA ... genomic variation, critically important for their association with human disease, but previously difficult ...
(Date:6/29/2015)... OH (PRWEB) , ... June 29, 2015 , ... ... support to healthcare providers for patients with certain neuropsychiatric and chronic pain conditions, ... President and CEO. , The appointments include: Peter Donato, Senior Vice President, Chief ...
(Date:6/29/2015)... ... June 29, 2015 , ... OR Manager announced Monday the launch of an ... well as a redesigned logo and weekly eLetter. The website contains the same informational ... and easier to navigate. , In addition to a refreshed look, http://www.ormanager.com ...
Breaking Medicine News(10 mins):Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3Health News:OR Manager Launches New Website 2
... By Jenifer Goodwin HealthDay Reporter , ... a good predictor of academic performance, but not necessarily ... tested the IQs and reading, spelling and math abilities ... the children,s social functioning through parental and teacher reports ...
... HealthDay Reporter , TUESDAY, Nov. 23 (HealthDay News) ... the year, many Americans will soon be subjected to radiation-emitting ... tide of concerns and complaints in recent weeks over body ... is too low to pose any serious health threat. ...
... 2010) - Even though most people are aware that good ... mother and child, misunderstandings about the safety of dental care ... dentist. The fact is that dentists can create a treatment ... adverse effects of oral disease during pregnancy. During the ...
... Reporter , TUESDAY, Nov. 23 (HealthDay News) -- Being born just ... child,s IQ and ability to pay attention, new research suggests. ... to those born between 34 to 36 weeks (called "late ... twice the risk of having an IQ score below 85 and ...
... HealthDay Reporter , MONDAY, Nov. 22 (HealthDay ... antioxidant cousin, alpha-carotene, in fruits and vegetables can lower ... disease and cancer, new research suggests. Both ... because of the red, yellow and orange coloring they ...
... , TUESDAY, Nov. 23 (HealthDay News) ... and efficiency while preventing sudden death among heart ... survival in real-world situations as they are in ... finding is based on an analysis of nearly ...
Cached Medicine News:Health News:For Autistic Kids, IQ May Not Predict School Achievement 2Health News:For Autistic Kids, IQ May Not Predict School Achievement 3Health News:Airport Body Scanners Safe, Experts Say 2Health News:Airport Body Scanners Safe, Experts Say 3Health News:Expecting? Don't neglect your teeth 2Health News: Children Born 'Late Pre-Term' More Prone to Low IQ 2Health News: Children Born 'Late Pre-Term' More Prone to Low IQ 3Health News:Eat Your Fruits & Veggies for Longer Life 2Health News:Eat Your Fruits & Veggies for Longer Life 3Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 2Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: